This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Bempedoic acid

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Bempedoic acid is a first-in-class, small-molecule inhibitor of ATP-citrate lyase, a component of the cholesterol biosynthesis pathway that works upstream of beta-hydroxy beta-methylglutaryl-coenzyme A.

  • Bempedoic acid is a prodrug that is activated by very-longchain acyl-CoA synthetase-1, an enzyme that is not present in skeletal muscle
    • therefore bempedoic acid acts on the same pathway as statins - however lack of the activating enzyme in skeletal muscle may prevent the muscular adverse effects associated with statins (1)

    • in phase 2 and phase 3 clinical trials, bempedoic acid significantly reduced atherogenic lipoproteins and high-sensitivity C-reactive protein (hsCRP) levels, and was associated with a low risk for adverse events typically associated with statins such as muscle-related symptoms and new-onset diabetes mellitus

  • the results of CLEAR (Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen) Serenity, a phase 3 clinical trial designed to evaluate the efficacy, safety and tolerability of bempedoic acid 180 mg daily versus placebo in statin-intolerant patients requiring lipid-lowering therapy for primary or secondary prevention of cardiovascular
    events (1):
    • study randomized 345 patients with hypercholesterolemia and a history of intolerance to at least 2 statins (1 at the lowest available dose) 2:1 to bempedoic acid 180 mg or placebo once daily for 24 weeks
    • primary end point was mean percent change from baseline to week 12 in low-density lipoprotein cholesterol
    • mean age was 65.2 years, mean baseline low-density lipoprotein cholesterol was 157.6 mg/dL, and 93% of patients reported a history of statin-associated muscle
      symptom
    • bempedoic acid treatment significantly reduced low-density lipoprotein cholesterol from baseline to week 12 (placebo corrected difference, -21.4% [95% CI, -25.1% to -17.7%]; P<0.001)
    • significant reductions with bempedoic acid versus placebo were also observed in non-high-density lipoprotein cholesterol (-17.9%), total cholesterol (-14.8%), apolipoprotein B (-15.0%), and high-sensitivity C-reactive protein (-24.3%; P<0.001 for all comparisons)
    • the study authors concluded that bempedoic acid was safe and well tolerated
      • most common muscle-related adverse event, myalgia, occurred in 4.7% and 7.2% of patients who received bempedoic acid or placebo, respectively

Consistent with inhibition of cholesterol synthesis, bempedoic acid significantly lowers elevated levels of LDL-C in hypercholesterolemic patients by 30% as monotherapy, up to an additional 24% when added on to stable statin therapy and up to 50% when combined with ezetimibe, suggestive of a distinct mechanism for LDL lowering (2,3,4,5).

Bempedoic acid used in combination with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor therapy (6):

  • a study of 2 Months of bempedoic acid treatment added to a PCSK9i therapy in patients with hypercholesterolemia reduced LDL-c levels further compared to those with a PCSK9i and placebo. The addition of bempedoic acid was safe and well-tolerated

Bempedoic acid significantly lowered LDL-C across glycaemic strata and did not worsen glycaemic parameters nor increase incidence of new-onset diabetes vs placebo over a median follow-up of 1 year (7)

Bempedoic acid as an adjunct to maximally tolerated statins was generally well tolerated and showed sustained efficacy in lowering LDL-c levels with up to 2.5 years of continuous treatment in patients with ASCVD (atherosclerotic cardiovascular disease) and/or HeFH (heterozygous familial hypercholesterolaemia) (8).

NICE suggest (9):

  • bempedoic acid with ezetimibe is recommended as an option for treating primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia as an adjunct to diet in adults. It is recommended only if:
    • statins are contraindicated or not tolerated,
    • ezetimibe alone does not control low-density lipoprotein cholesterol well enough, and
    • the company provides bempedoic acid and bempedoic acid with ezetimibe according to the commercial arrangement
  • bempedoic acid with ezetimibe can be used as separate tablets or a fixed-dose combination

The CLEAR Outcomes study (10):

  • a double-blind, randomized, placebo-controlled trial involving patients who were unable or unwilling to take statins owing to unacceptable adverse effects ("statin-intolerant" patients) and had, or were at high risk for, cardiovascular disease
    • patients were assigned to receive oral bempedoic acid, 180 mg daily, or placebo
    • primary end point was a four-component composite of major adverse cardiovascular events, defined as death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization
  • showed that among statin-intolerant patients, treatment with bempedoic acid was associated with a lower risk of major adverse cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization)
    • at 6 months, bempedoic acid reduced LDL-c by 21.7% and hsCRP by 22.2%. In comparison, a 0.6% reduction in LDL-c and an increase of 2.2% in hsCRP was observed in the placebogroup at 6 months.
    • bempedoic acid reduced the primary endpoint of 4-component MACE by 13% (HR 0.87, 95%CI 0.79-0.96, P=0.004, ARR 1.6%, NNT 63)

A review with respect to bempedoic acid and the CLEAR study stated (11):

  • bempedoic acid is licensed for primary hypercholesterolaemia or mixed dyslipidaemia alone or alongside statins and other lipid-lowering therapies.
  • it has been shown to moderately lower low-density lipoprotein cholesterol in clinical trials but evidence of its effect on cardiovascular outcomes has been lacking.
  • a study found that in statin-intolerant patients, it reduced the risk of a composite outcome of four major adverse cardiovascular events.

Reference:

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.